[Funding alert] Croatian-based GlycanAge Raises €3.9 Million in Seed Funding

Monday 19, 2024 | By Startup Rise EU

Croatian-based GlycanAge raises €3.9 million in seed funding. Leading this investment were UK-based deep-tech fund Kadmos Capital and LAUNCHub Ventures. In terms of the company's mission to reinvent individualized preventative healthcare, this is a significant advancement.

Croatian-based GlycanAge raises €3.9 million in seed funding. Leading this investment were UK-based deep-tech fund Kadmos Capital and LAUNCHub Ventures. In terms of the company's mission to reinvent individualized preventative healthcare, this is a significant advancement.

Read also - London-based Kynd Secures an Undisclosed Amount Funding

Despite its potential, the study of glycobiology has historically faced obstacles due to the lack of required tools and the intrinsic scientific complexity of the field.

However, because of technological advancements that highlight the enormous potential of glycobiology in illness prediction, intervention guidance, and therapy customization, the landscape is fast shifting.

Read also - Oxford-based MeVitae Raises €1.7 Million in Seed Funding

Gordan Lauc, the Chief Scientific Officer and co-founder of GlycanAge, is at the center of these developments. Dr. Lauc has contributed significantly to the advancement of high throughput glycomic analysis and the use of glycan biomarkers in precision medicine, working in tandem with his team. Dr. Lauc made a big move in 2017 when he started the Human Glycome Project.

The goal of this research is to develop glycomics as a key tool for patient stratification, illness identification, and therapy response monitoring. Recent research confirms the vital role glycans play in the biological processes of the body, showing that they are altered in more than 70 diseases and sometimes even up to ten years before symptoms and a diagnosis are made.

Read also - UK-based Codestone Acquired Cloud Business

Nikolina Lauc, CEO of GlycanAge, said: “We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being.”

The strategic move from the longevity industry to the larger diagnostics market will be made possible in large part by the recently raised money. With the help of this funding, GlycanAge will be able to create a well-defined regulatory plan and product pipeline in order to develop predictive biomarkers unique to individual diseases.

Read also - Dutch-based Phycom Raises €1.75Million in Fresh Round Funding

Lyuben Belov, Managing Partner, LAUNCHub Ventures, commented: “As scientific research in age-related diseases progresses, the fields of diagnostic and preventive medicine appear very promising in combating such diseases and improving health outcomes. Key trends, such as the widespread adoption of biomarkers and D2C testing, along with the application of AI and advanced analytics, provide an opportunity for a significant impact on the overall health status of billions of people. Investing in GlycanAge represents our commitment to health and longevity in Europe. The innovative work in glycobiology is redefining personalized care, promising a future where health is tailored and proactive. We’re excited to back Nikolina Lauc and Dr. Gordan Lauc’s vision, making longevity a reality for all.”

John Gebeily, Partner of Kadmos Capital, added: “With the pace of change now faster than ever, it’s vital to back high-impact technologies that will deliver solutions to tomorrow’s biggest problems. GlycanAge’s vision lies at the crossroad between preventative healthcare, diagnostics and longevity. We are delighted to back Nikolina Lauc and Dr.Gordan Lauc and congratulate them on their accomplishments. We are sure they will leave their mark on the future of healthcare.”

The EU financing emphasizes GlycanAge's dedication to incorporating cutting-edge technology into its methodology and is specifically intended to bridge the innovation gap between artificial intelligence and diagnostics.

Read also - Paris-based Avatar Medical Secures €5 Million in Seed Funding

About GlycanAge

GlycanAge, their contemporary way of life has fundamentally altered how we live and can have positive or negative effects on their health. A crucial component that was mostly disregarded until recently has been made clear by science. The age you were born.

Read also -  Delft-based AgriData Innovations Secures Undisclosed Funding

GlycanAge is a revolutionary, yet easy-to-use test that examines your glycobiology. A critical first step in bettering your health is to take the GlycanAge® test. You may learn about and keep track of your biological age thanks to the findings of your exam.

Recommended Stories for You

story
News

German-based Octomind Secures $4.8 Million in Seed Funding

Startup Rise EU Tuesday 23, 2024

story
News

Dublin-based SynOx Therapeutics Secures $75Million in Series B Round Funding

Startup Rise EU Tuesday 23, 2024

story
News

Paris-based Zefir Secures €11Million in Funding

Startup Rise EU Tuesday 23, 2024

story
News

Helsinki-based HappySignals Secures €12 Million in Funding

Startup Rise EU Tuesday 23, 2024

story
News

Italian-based Lithium Lasers Secures €2 Million in Funding

Startup Rise EU Monday 22, 2024

story
News

[Funding alert] Munich-based Smart Reporting Secures €23 Million in Series C Round Funding

Startup Rise EU Monday 22, 2024